Life-saving Device For Type 1 Diabetes Too Expensive

Life-saving device for type 1 diabetes too expensive

Life-saving device for type 1 diabetes too expensive

A small device has revolutionised the lives of those with type 1 diabetes, including the life of Burnie man Troy Wilkins.
Life-saving: Troy Wilkins will not be able to afford to continue to use CGM technology because of the prohibitive costs. Picture: Sarah Lansdown
Continuous glucose monitoring (CGM) is a technology where patients have a small filament inserted into the skin that sends a blood glucose reading to a monitor every five minutes, day and night.
Since trialing the technology through a grant from type 1 diabetes advocacy charity the Danii Foundation, Mr Wilkins said the device has saved his life by alerting him to dangerously low blood sugar levels.
“I had no idea before I started that my blood sugar levels were dropping critically low every single night,” he said.
Type 1 diabetes is an autoimmune disease which destroys the insulin-creating cells in the pancreas, leaving the patient to rely on daily insulin injections and around-the-clock monitoring. There is no known cause or cure.
While CGM offers the most effective and least intrusive way to monitor the condition and avoid “dead in bed syndrome”, Mr Wilkins said he won’t be able to continue after his trial because the cost is too high.
“I’m worried that I’m not going to wake up the next morning because I’m going to have low blood sugar overnight,” Mr Wilkins said.
The technology costs between $3500 and $6000 per year.
The Danii Foundation was involved in lobbying the federal government for funding of CGM for under 21 year olds.
I’m worried that I’m not going to wake up the next morning Continue reading

Rate this article
Total 1 ratings
'Reverse vaccine' for Type 1 diabetes seems to pass human test

'Reverse vaccine' for Type 1 diabetes seems to pass human test

Attempts at new treatments and cures have focused on suppressing large portions of the immune system — sometimes using powerful drugs developed for other conditions, such as the blood cancer lymphoma. Steinman called this the "big hammer" approach.
"We're trying to do something different," he said. "We want to eliminate just the immune cells that attack the insulin-producing cells in the pancreas."
Steinman and his team designed a molecule that contained the gene for making proinsulin, the precursor to insulin. The molecule also included instructions for triggering the killer cells' response and then shutting it down.
If everything went as planned, the DNA molecule would suppress the killer cells and allow the pancreatic cells to function properly, producing insulin.
After successful trials with diabetic mice, the team prepared to test its vaccine on humans. They selected 80 volunteers ages 18 to 40 who had been diagnosed with Type 1 diabetes within the last five years. After that time, many Type 1 sufferers have already lost all of their insulin-producing cells, Steinman said. (Although many people with Type 1 diabetes are diagnosed as children, the researchers avoided testing their reverse vaccine on kids because of safety concerns.)
Two-thirds of the study volunteers received the reverse vaccine in one of four doses ranging from 0.3 to 6.0 milligrams. The rest of the volunteers got a placebo. Injections were made once a week for 12 weeks.
Throughout the study, both the experimental and placebo groups also received insulin replacement therapy. All subjects were monitore Continue reading

Call to 'suspend' diabetes drug

Call to 'suspend' diabetes drug

A widely-used diabetes drug should be pulled from the market, European regulators say.
Avandia is used to control blood sugar levels in type 2 diabetes patients.
It was licensed 10 years ago and more than 100,000 patients in the UK use it despite on-going concerns linking it to heart problems.
After reviewing safety data, the European Medicines Agency said the benefits no longer outweighed the risks and it should be suspended.
The drug - generic name rosiglitazone - is also used in combination with other drugs under the names Avandamet and Avaglim.
A spokeswoman for the regulator said: "Patients who are currently taking these medicines should make an appointment with their doctor to discuss suitable alternative treatments.
"Patients are advised not to stop their treatment without speaking to their doctor."
It should not take this long to come to a decision when there is evidence that people's lives may be at riskPeter Walsh, Action Against Medical Accidents
But the recommendation in Europe contrasts with the US where regulators have decided only to introduce tougher restrictions over its use - a verdict which they confirmed at the same time as the EMA announcement.
Avandia was originally licensed with warnings about the risks for patients with heart failure.
These were later expanded to include other heart problems after further research into its use.
The advice by an expert panel of advisers, who looked at the issue amid mounting concerns, will now be passed to the European Commission.
It may be several months before they make a final ruling, although it is unusua Continue reading

No more pages to load

Popular Articles

  • Too little gluten in our diet may increase the risk of type 2 diabetes

    People with celiac disease or who are gluten intolerant may benefit from a low-gluten diet. A considerable number of people who do not have these diseases still adopt a gluten-free diet in the hope that it benefits their health. New research, however, suggests that a low-gluten diet may even have some adverse health effects, by raising the risk of diabetes. Gluten is a protein mainly found in whea ...

  • My Way-Too-Sweet Sixteen: A Type 1 Diabetes Diagnosis Story

    My Way-Too-Sweet Sixteen: A Type 1 Diabetes Diagnosis Story My Way-Too-Sweet Sixteen: A Type 1 Diabetes Diagnosis Story The theory in my family is that my pancreas had been dying a slow death for fifteen years. A cows milk-related allergy (so the family lore unfurled) had spelled doom for this most delicate of organs before I could even walk. But lets give credit where credits due: my pancreas ...

  • Israeli device banishes finger-pricking for sugar levels in diabetes patients

    Diabetes patients know that one of the greatest challenges in managing the ailment is tracking their blood sugar, or glucose, levels. To do that the only option available today is through the use of standard glucose meters — devices that require multiple finger pricks each day, a painful process. For years, researchers have been trying to find a noninvasive, quicker and easier way to monitor blo ...

  • Abbott wins FDA approval for diabetes device that doesn't require routine finger pricks

    The U.S. Food and Drug Administration approved Abbott’s FreeStyle Libre Flash Glucose Monitoring System for adults, which already is sold in 41 other countries. Abbott Laboratories has gained clearance to start selling in the U.S. the first continuous glucose monitor that does not require people with diabetes to routinely prick their fingers. The U.S. Food and Drug Administration on Wednesday ap ...

  • New device for diabetes eliminates the need for painful finger pricking

    Source:Supplied AUSTRALIAN adults with diabetes now have the option of using a new glucose monitoring device, which eliminates the need for regular finger pricking. The system, which has been available in Europe for several years, involves a small sensor the size of a 20 cent coin worn on the upper arm for 14 days. Many diabetics have to draw blood and test their blood glucose levels up to 12 time ...

  • An 11-Year-Old Has 3D-Printed a Device That Safely Stores Diabetes Test Strips

    It's well established that diabetes wreaks havoc on people's blood sugar levels, but one thing we don't usually think about is the amount of waste produced by all those blood tests that need to be taken daily when you have the disease. Now 11-year-old William Grame from Canberra in Australia has 3D printed a device that hygienically stores all those old blood test strips, and it's small enough to ...

  • New stick-on diabetes device offers a break from finger pricking

    Diabetics who must prick their fingers to test blood sugar levels every day often end up with sore and calloused hands – which is why needle-free devices are always a welcome arrival in the treatment market. A gadget developed under British scientist Jared Watkin is now on the scene that can be worn on the back of the upper arm and monitors glucose levels for up to 14 days. The Libre sensor can ...

  • News Flash: The FDA Just Approved a Breakthrough Diabetes Device

    Diabetes is often referred to in the medical community as the "silent killer." Affecting more than 30 million people in the U.S. (9.4% of the population), diabetes was listed the cause of death for nearly 80,000 people in 2016, according to the Centers for Disease Control and Prevention. Its comorbidities, such as hypertension, heart disease, and kidney disease, can also cause lifelong problems an ...

  • Diabetes device scrutinizes sweat for a week at a time

    While there are already biosensors that help people manage type 2 diabetes, they're single-use devices that have to be replaced on a daily basis. That could be about to change, however, thanks to research being conducted by scientists from the University of Texas at Dallas. Led by Prof. Shalini Prasad, they've created a diabetes-monitoring tool that's good for up to a week. Worn on the wrist like ...

Related Articles